Healthcare

Short-selling, the act of buying a stock high and betting that its price will take a dive in the future, isn’t every investor’s cup of tea. However, for those that have the stomach for it, investment Guru Andrew Left of Citron Research might be an inspiration. While short-investing isn’t necessarily something that novice investors... Read more

Johnson & Johnson (NYSE: JNJ) is the biggest healthcare company in the U.S in terms of market value. But the stock has been losing value amid concerns around the company’s businesses. Investors are mainly concerned about J&J’s losing traction of its prostate cancer medicine Zytiga and rheumatoid arthritis drug Remicade amid problems of generic... Read more

The dividend aristocrats, a group of high quality companies, has rewarded shareholders with safe and reliable income for many years. However, sometimes, a company falls out from the list due to increased competition or weaker business models. In this article, we shall take a look at Cardinal Health, the medical supplier and try to... Read more

Penny Stocks are very sensitive to the day’s headlines. That’s why many Penny Stock holders are speculators, preferring to buy the rumor and sell the news. However, there are some penny stock stories that investors might actually believe in.  Therefore may be willing to be more patient with their holdings. For such patient investors,... Read more

Medtronic is one of those companies you don’t need a reason for buying. You need a reason for not buying it. With a proven track record, healthy financials and a solid future catalyst, Medtronic should do very well for patient investors. But make sure you understand that this is a company you buy with... Read more

Johnson & Johnson (NYSE: JNJ) is in the news after the company said its CFO will step down. Irrespective of the executive changes, let’s dig deeper and analyze Johnson & Johnson stock and see why it’s worth buying. Johnson & Johnson is swiftly diversifying its revenue stream amid challenges in the traditional consumer products division. Johnson... Read more

Shareholders of Omega Healthcare Investors (NYSE:OHI) has seen their holdings decrease for quite some time. In 2017, the stock decreased 20% and in the past three years, the total price return has been 37.17%. However, if one focus on total return, the investment hasn’t been that bad. Omega Healthcare Investors yields close to 10%,... Read more

2017 was not a good year for Gilead Sciences, Inc. (NASDAQ:GILD), as the company announced weak sales of core hepatitis C drugs Harvoni, Sovaldi and Epclusa. These drugs are under pressure amid pricing problems and competition. Gilead also recently posted fourth quarter results that were not up to the expectations. Total HCV franchise revenue... Read more

The latest rumour has it that Warren Buffet, Jeff Bezos and Jamie Dimon will team up to disrupt the healthcare sector. They say that healthcare prices and pharmaceutical prices are way too high, and that they share a common goal about helping fellow Americans. However, the main goal is to create an independent health... Read more

Aimmune Therapeutics Inc. (NASDAQ: AIMT), is currently developing therapies for peanut and other food allergies using its Characterized Oral Desensitization Immunotherapy (CODIT) system. The company’s lead biologic candidate for peanut allergies, AR101, completed a Phase 2 study a couple years ago with surprisingly positive results The Phase 2 study, which consisted of 23 patients (both... Read more